Skip to content
6-K

Foreign Interim / Material

Freeline Therapeutics Holdings plc

0000950170-23-067157

← back to feed
Filed
Dec 1, 2023 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted Q3 2023 · Sep 30, 2023 65.22M sh
Shares Diluted Q3 2023 · Sep 30, 2022 57.38M sh
Capex Q3 2023 · Sep 30, 2023 $654K
Capex Q3 2023 · Sep 30, 2022 $3.12M
Operating Cash Flow Q3 2023 · Sep 30, 2023 −$44.39M
Operating Cash Flow Q3 2023 · Sep 30, 2022 −$58.37M
Cash And Equivalents Q3 2023 · Sep 30, 2023 $29.45M
Cash And Equivalents Q3 2023 · Dec 31, 2022 $47.28M
Cash And Equivalents Q3 2023 · Sep 30, 2022 $65.85M
Stockholders Equity Q3 2023 · Sep 30, 2023 $30.04M
Stockholders Equity Q3 2023 · Dec 31, 2022 $52.41M
Stockholders Equity Q3 2023 · Sep 30, 2022 $68.58M
Stockholders Equity Q3 2023 · Dec 31, 2021 $120.44M
Current Liabilities Q3 2023 · Sep 30, 2023 $17.48M
Current Liabilities Q3 2023 · Dec 31, 2022 $30.97M
Total Liabilities Q3 2023 · Sep 30, 2023 $19.18M
Total Liabilities Q3 2023 · Dec 31, 2022 $34.23M
Current Assets Q3 2023 · Sep 30, 2023 $34M
Current Assets Q3 2023 · Dec 31, 2022 $67.63M
Total Assets Q3 2023 · Sep 30, 2023 $49.22M
Total Assets Q3 2023 · Dec 31, 2022 $86.64M
Eps Diluted Q3 2023 · Sep 30, 2023 −$0.41
Eps Diluted Q3 2023 · Sep 30, 2022 −$1.15
Eps Basic Q3 2023 · Sep 30, 2023 −$0.41
Eps Basic Q3 2023 · Sep 30, 2022 −$1.15
Sga Expense Q3 2023 · Sep 30, 2023 $24M
Sga Expense Q3 2023 · Sep 30, 2022 $25.01M
Rd Expense Q3 2023 · Sep 30, 2023 $25.51M
Rd Expense Q3 2023 · Sep 30, 2022 $53.56M
Net Income Q3 2023 · Sep 30, 2023 −$26.93M
Net Income Q3 2023 · Sep 30, 2022 −$65.97M
Operating Income Q3 2023 · Sep 30, 2023 −$48M
Operating Income Q3 2023 · Sep 30, 2022 −$78.57M
Revenue Q3 2023 · Sep 30, 2023 $622K